T-cell treatment for certain viral infections in weakened cancer immunity
Part of Blood & lymphatic, Cancer, Infections clinical trials.
This Phase 1 study tests whether a lab-made immune cell treatment that targets viruses can be given safely in people with weakened immune systems after cancer treatment or transplant. It also looks at whether it helps control infections such as BK, adenovirus, CMV, JC virus, or COVID-19.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have one of these documented viral infections: BK virus, adenovirus, CMV, JC virus, or COVID-19 with lung involvement.
- If you have BK, adenovirus, or CMV, you previously had a bone marrow or stem cell transplant from another person (allogeneic HSCT).
- If you have JC virus or COVID-19, you do NOT need a prior stem cell transplant to qualify.
- You must be able to sign consent (or have a legal decision-maker sign).
- You must not have had certain recent immune treatments (ATG in the last 14 days, or donor lymphocyte infusion/Campath in the last 28 days).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment using special immune cells (called cytotoxic T lymphocytes) to fight BK or JC virus infections in people with weakened immune systems, such as cancer patients or organ transplant recipients. It may help control the virus and reduce related complications.
This early-phase study tests donor immune cells (T cells) to treat people who have adenovirus infection or adenovirus-related disease but have a weakened immune system. It may help your body fight the virus, especially in cases where other treatments may not be enough.
This early-phase (Phase 1) study tests an immune cell treatment (R-MVST) to help people whose immune system has been weakened by a past transplant and who keep getting viral infections reactivated or not responding well to standard treatment. It may help your body control viruses like EBV, CMV, adenovirus, or BK virus.
This trial tests a special immune cell treatment (R-MVST cells) for children and young adults who have had a stem cell or organ transplant and are fighting stubborn viral infections like EBV, CMV, ADV, or BK virus. The goal is to see if these cells can help control the viruses when standard medicines haven't worked well enough.
This trial studies whether directly infusing donor-made immune cells (virus-fighting T-cells) is safe and feasible in people who still have viral infections after a stem cell transplant. It may help your body control infections from adenovirus, CMV, or EBV when standard antiviral treatments aren’t working.
This Phase 1 study tests an “off-the-shelf” type of immune cell therapy made to attack several viruses (EBV, CMV, adenovirus, and BK, and possibly JC) in people who had an allogeneic stem cell transplant and still have ongoing viral infection. It may help your body control the virus when standard treatments have not worked or you cannot tolerate them.
Hear when a new Adenovirus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.